An Evaluation of the Long-term Efficacy and Safety of Methylone for the Treatment of PTSD

Summary

This is an extension study of participants who previously completed a Transcend-sponsored clinical trial evaluating TSND-201 as a treatment for PTSD. Participants will be followed for up to 52 weeks. During the 52 week period, PTSD symptoms and safety will be assessed monthly. Participants' PTSD symptoms will be assessed at each observational visit and if criteria for Relapse has been met, participants may be eligible to receive a course of TSND-201 treatment.

Timeline

Start

2024-03-06

Primary completion

2025-10-06

Completion

2025-10-06

Drugs

Indications